Id: acc2446
Group: 2sens
Protein: TRIP13
Gene Symbol: TRIP13
Protein Id: Q15645
Protein Name: PCH2_HUMAN
PTM: phosphorylation
Site: Tyr56
Site Sequence: NRHNIVFGDYTWTEFDEPFLT
Disease Category: Cancer
Disease: Head and Neck Cancer
Disease Subtype:
Disease Cellline: UM-SCC-1
Disease Info:
Drug: cetuximab
Drug Info: "Cetuximab is a recombinant human-mouse chimeric monoclonal antibody that specifically binds to the epidermal growth factor receptor (EGFR), competitively inhibiting ligand binding and blocking downstream signaling pathways, thereby inhibiting cancer cell proliferation, inducing apoptosis, and reducing the production of matrix metalloproteinases and vascular endothelial growth factor; it is used in combination with irinotecan for EGFR-positive, irinotecan-resistant metastatic colorectal cancer, as a monotherapy for patients intolerant to irinotecan, and in combination with radiotherapy for locally advanced head and neck squamous cell carcinoma. "
Effect: sensitize
Effect Info: Phosphorylation of TRIP13 at Y56 induces radioresistance but renders head and neck cancer sensitive to cetuximab.
Note:
Score: 5.0
Pubmed(PMID): 34111559
Sentence Index:
Sentence:

Sequence & Structure:

MDEAVGDLKQALPCVAESPTVHVEVHQRGSSTAKKEDINLSVRKLLNRHNIVFGDYTWTEFDEPFLTRNVQSVSIIDTELKVKDSQPIDLSACTVALHIFQLNEDGPSSENLEEETENIIAANHWVLPAAEFHGLWDSLVYDVEVKSHLLDYVMTTLLFSDKNVNSNLITWNRVVLLHGPPGTGKTSLCKALAQKLTIRLSSRYRYGQLIEINSHSLFSKWFSESGKLVTKMFQKIQDLIDDKDALVFVLIDEVESLTAARNACRAGTEPSDAIRVVNAVLTQIDQIKRHSNVVILTTSNITEKIDVAFVDRADIKQYIGPPSAAAIFKIYLSCLEELMKCQIIYPRQQLLTLRELEMIGFIENNVSKLSLLLNDISRKSEGLSGRVLRKLPFLAHALYVQAPTVTIEGFLQALSLAVDKQFEERKKLAAYI

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No data.

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
Y 56 U Glioblastoma Phosphorylation 32860853

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: